-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 5, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases,
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 28, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in a
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 28, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2021
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 10, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple
MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on three XmAb ®
MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 3, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief
— Collaboration joins together Xencor's modular XmAb engineered protein platforms with UCLA's expertise in biology to rapidly create and advance potential new medicines — MONROVIA, Calif. & LOS ANGELES --(BUSINESS WIRE)--Feb. 25, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 23, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases,
MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 16, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter and full year
MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two
